Approval · Notice of Compliance 16787 · 2015
DOMPERIDONE: Notice of Compliance 16787
Issued April 9, 2015
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16787
- Date
- April 9, 2015
- Company
- Ranbaxy Pharmaceuticals Canada Inc.Brampton, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Update to the safety information in the product monograph
- Therapeutic class
- Modifier of upper gastrointestinal motility
- Canadian reference product
- APO-DOMPERIDONE (Apotex Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| DOMPERIDONE | Not yet assigned | — |
Medicinal ingredients
- DOMPERIDONE MALEATE 10 MG per MG